This protocol addresses patients presenting with the autoimmune hepatitis / primary sclerosing cholangitis (AIH/PSC) overlap variant syndrome — a distinct clinical entity that combines features of both conditions and requires a tailored treatment strategy.
The AIH/PSC variant represents an overlap between autoimmune hepatitis and primary sclerosing cholangitis. This population — both adult and paediatric — carries specific management considerations that differ from either condition treated in isolation.
Current evidence supports a combination strategy involving immunosuppressive therapy alongside ursodeoxycholic acid (UDCA) for patients with this variant syndrome.